Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Vulvar Neoplasms 1Uterine Cervical Neoplasms 1Rectal Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Carcinoma, Squamous Cell 1Breast Neoplasms 1Anus Neoplasms 1

Interventions

Radiotherapy 5Mitomycin 5Fluorouracil 5Watchful Waiting 3Paclitaxel 3Nivolumab 3Cisplatin 3Vaccines 2Radiation 2Observation 2Light Coagulation 2Carboplatin 2Capecitabine 2pembrolizumab 1nanocis 1cemiplimab 1atezolizumab 1X-Rays 1Vaccines, Synthetic 1Technetium-99 1Taxes 1Specimen Handling 1Sigmoidoscopy 1Proctoscopy 1Phantoms, Imaging 1Papillomavirus Vaccines 1Octreotide 1Neoadjuvant Therapy 1Mitomycins 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Anus Neoplasms × nanocis × Clear all
NCT02997553 2023-01-09

GASVERT

Institut de Cancérologie de Lorraine

Phase 3 Completed
744 enrolled
BreastDermatologicGastrointestinalGynecologicHead & Neck

Anus Neoplasms, Breast Neoplasms, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms, Rectal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡